This post was originally published on this site Targeting a single enzyme called PI3K-delta prevented neuroinflammation, reduced the accumulation of toxic amyloid-beta plaques in the brain, and prevented memory deficits in a mouse model of Alzheimer’s disease, a new study shows. This approach, which also increased the animals’ life span, may represent a potential new…
About Alzheimer’s Disease
Walking into a room and forgetting why you went into the room is normal. Walking into a room and forgetting what room you are in is not normal. Alzheimer’s disease is the most common form of dementia and affects one in ten people over the age of 65. Unfortunately, the exact cause of Alzheimer’s disease is not fully understood however leading scientific experts in the field attribute the illness to the irreversible and progressive generalized degeneration of the brain. Alzheimer’s disease goes well beyond the forgetfulness that may accompany aging, and typically first signs include difficulty remembering current information or performing new tasks. Ongoing hallmark symptoms include impaired memory function, difficulty performing everyday tasks, and neurobehavioral abnormalities. Currently, there is no known cure for Alzheimer’s disease, and multi-disciplinary treatment focuses on symptom management and limiting progression.
Conditions
Alzheimer’s News
Protect Alzheimer’s Patients from Information Overload
This post was originally published on this site We live in a global society, and within our society terrible things happen. We indirectly face tragedy every day. We’re constantly bombarded by breaking news that keeps us reeling. It is a hard reality for those of us with healthy minds, but it is even more disturbing…
Alzheimer’s Patient Reverted Back to Earlier Writing Style after Diagnosis, Reveals Analysis of Woman’s Long-term Journals
This post was originally published on this site The writing style of a woman’s diary entries over 31 years has given researchers a glimpse into the progression of her cognitive decline from Alzheimer’s disease, revealing a relationship between language use and the transition from healthy to severe dementia. University of Toronto (UT) researchers specializing in…
Oral Anticoagulant Dabigatran Prevented Memory Loss in Mouse Model of Alzheimer’s, Study Shows
This post was originally published on this site Oral treatment over one year with an approved blood thinner called dabigatran prevented memory loss, preserved blood circulation in the brain and reduced the amount of senile plaques in a mouse model of Alzheimer’s disease. The study with that finding, “Long-Term Dabigatran Treatment Delays Alzheimer’s Disease Pathogenesis…
Long-term Extension Study of Anavex 2-73, Potential Treatment of Alzheimer’s Dementia, Opens
This post was originally published on this site Anavex Life Sciences has launched an extension study — called ATTENTION-AD — to investigate the long-term safety and efficacy of Anavex 2-73 in delaying cognitive decline in people with early Alzheimer’s disease. Eligible patients are those now taking part in the company’s 48-week ANAVEX2-73-AD-004 study underway in…
These Essential Supplies Make Caregiving a Little Easier
This post was originally published on this site The hardest job becomes easier when the right supplies are on hand. This is especially true with caregiving. Every day is a learning experience. We learn what is essential for the care and the service of the person we are caring for. The following tools and materials…
Nuplazid Significantly Delays Relapses in Dementia-related Psychosis, Phase 3 Study Shows
This post was originally published on this site Treatment with Nuplazid (pimavanserin) significantly delays time to a psychosis relapse in people with dementia-related disorders such as Alzheimer’s and Parkinson’s diseases, according to results from the ongoing Phase 3 HARMONY study. Evaluation by an independent data monitoring committee recommended an early stop to this trial based on the treatment’s “robust”…
NDX-1017 Phase 1 Trial Complete, Results Will Be Presented at CTAD Conference, Athira Says
This post was originally published on this site Athira Pharma has completed the Phase 1 trial testing NDX-1017, its lead therapeutic candidate for Alzheimer’s disease, and will present the results at the 12th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference in December. Preliminary results showed the therapy, which has the potential to be regenerative and…
NIA Launches Research Centers to Advance Drug Discovery in Alzheimer’s
This post was originally published on this site To advance the pipeline for innovative therapeutics in Alzheimer’s (AD), the National Institute on Aging (NIA) will invest an expected $73 million over five years in two new translational research centers. The centers will be funded through the NIA’s Alzheimer Centers for the Discovery of New Medicines program,…
My Sister’s Breast Cancer Diagnosis Taught Us an Important Lesson About Caregiving
This post was originally published on this site October is Breast Cancer Awareness Month, but what does that have to do with Alzheimer’s disease and caregiving? Nothing, except that women make up the majority of caregivers in the United States. This means that over 60 percent of caregivers are susceptible to breast cancer. Breast cancer…
$53M NIA Grant Will Test Alzheimer’s Care in Real-world Settings
This post was originally published on this site The National Institute on Aging (NIA) has awarded a five-year grant expected to total $53.4 million to Brown University and Hebrew SeniorLife to lead the creation and management of a research incubator to test Alzheimer’s and dementia care interventions in real-world settings. Called the NIA Imbedded Pragmatic AD/ADRD Clinical…
Carefully Targeting Brain Immune Cells May Help Prevent Amyloid-beta Plaques, Study Suggests
This post was originally published on this site Therapeutics that target brain immune cells known as microglia may prevent the formation of amyloid-beta plaques, one of the hallmarks of Alzheimer’s disease, according to a recent mouse study. The study, ”Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model,” was…